INHIBIKASE THERAPEUTICS INC (IKT) Stock Fundamental Analysis

NASDAQ:IKT • US45719W2052

1.67 USD
+0.03 (+1.83%)
At close: Feb 13, 2026
1.65 USD
-0.02 (-1.2%)
After Hours: 2/13/2026, 8:17:16 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall IKT gets a fundamental rating of 3 out of 10. We evaluated IKT against 522 industry peers in the Biotechnology industry. While IKT has a great health rating, there are worries on its profitability. IKT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year IKT has reported negative net income.
  • In the past year IKT has reported a negative cash flow from operations.
  • IKT had negative earnings in each of the past 5 years.
  • In the past 5 years IKT always reported negative operating cash flow.
IKT Yearly Net Income VS EBIT VS OCF VS FCFIKT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M -25M

1.2 Ratios

  • With a Return On Assets value of -59.87%, IKT perfoms like the industry average, outperforming 43.49% of the companies in the same industry.
  • IKT has a Return On Equity (-65.37%) which is in line with its industry peers.
Industry RankSector Rank
ROA -59.87%
ROE -65.37%
ROIC N/A
ROA(3y)-77.15%
ROA(5y)-57.11%
ROE(3y)-96.05%
ROE(5y)-71.15%
ROIC(3y)N/A
ROIC(5y)N/A
IKT Yearly ROA, ROE, ROICIKT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K

1.3 Margins

  • IKT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IKT Yearly Profit, Operating, Gross MarginsIKT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • IKT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IKT has been increased compared to 1 year ago.
  • Compared to 5 years ago, IKT has more shares outstanding
  • IKT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IKT Yearly Shares OutstandingIKT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
IKT Yearly Total Debt VS Total AssetsIKT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • An Altman-Z score of 15.08 indicates that IKT is not in any danger for bankruptcy at the moment.
  • IKT has a Altman-Z score of 15.08. This is amongst the best in the industry. IKT outperforms 86.78% of its industry peers.
  • IKT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 15.08
ROIC/WACCN/A
WACC8.68%
IKT Yearly LT Debt VS Equity VS FCFIKT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 11.73 indicates that IKT has no problem at all paying its short term obligations.
  • IKT's Current ratio of 11.73 is amongst the best of the industry. IKT outperforms 86.59% of its industry peers.
  • A Quick Ratio of 11.73 indicates that IKT has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 11.73, IKT belongs to the best of the industry, outperforming 86.59% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.73
Quick Ratio 11.73
IKT Yearly Current Assets VS Current LiabilitesIKT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • IKT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.04%, which is quite impressive.
  • Looking at the last year, IKT shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)66.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • IKT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.17% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y79.78%
EPS Next 2Y33.72%
EPS Next 3Y21.17%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IKT Yearly Revenue VS EstimatesIKT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2026 2027 1M 2M 3M 4M
IKT Yearly EPS VS EstimatesIKT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • IKT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IKT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IKT Price Earnings VS Forward Price EarningsIKT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IKT Per share dataIKT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • IKT's earnings are expected to grow with 21.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.72%
EPS Next 3Y21.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for IKT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INHIBIKASE THERAPEUTICS INC

NASDAQ:IKT (2/13/2026, 8:17:16 PM)

After market: 1.65 -0.02 (-1.2%)

1.67

+0.03 (+1.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-25
Inst Owners42.79%
Inst Owner Change42.37%
Ins Owners1.97%
Ins Owner Change10.14%
Market Cap201.90M
Revenue(TTM)N/A
Net Income(TTM)-47.66M
Analysts83.64
Price Target6.12 (266.47%)
Short Float %7.19%
Short Ratio12.97
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.01%
Min EPS beat(2)-21.01%
Max EPS beat(2)0.99%
EPS beat(4)1
Avg EPS beat(4)-137.88%
Min EPS beat(4)-471.19%
Max EPS beat(4)0.99%
EPS beat(8)4
Avg EPS beat(8)-73.63%
EPS beat(12)6
Avg EPS beat(12)-48.96%
EPS beat(16)8
Avg EPS beat(16)-37.6%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.14%
PT rev (3m)-25%
EPS NQ rev (1m)3.96%
EPS NQ rev (3m)9.34%
EPS NY rev (1m)3.31%
EPS NY rev (3m)0.28%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.77
P/tB 2.77
EV/EBITDA N/A
EPS(TTM)-0.91
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0
BVpS0.6
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -59.87%
ROE -65.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-77.15%
ROA(5y)-57.11%
ROE(3y)-96.05%
ROE(5y)-71.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 676.65%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.73
Quick Ratio 11.73
Altman-Z 15.08
F-Score6
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)802.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next Y79.78%
EPS Next 2Y33.72%
EPS Next 3Y21.17%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-117.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-131.4%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-39.66%
OCF growth 3YN/A
OCF growth 5YN/A

INHIBIKASE THERAPEUTICS INC / IKT FAQ

What is the ChartMill fundamental rating of INHIBIKASE THERAPEUTICS INC (IKT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to IKT.


Can you provide the valuation status for INHIBIKASE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to INHIBIKASE THERAPEUTICS INC (IKT). This can be considered as Overvalued.


What is the profitability of IKT stock?

INHIBIKASE THERAPEUTICS INC (IKT) has a profitability rating of 1 / 10.


Can you provide the financial health for IKT stock?

The financial health rating of INHIBIKASE THERAPEUTICS INC (IKT) is 8 / 10.